Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.

Background: Ecnoglutide is a novel biased GLP-1 receptor agonist that preferentially activates the cAMP pathway over β-arrestin recruitment. We aimed to assess both non-inferiority and superiority of ecnoglutide versus dulaglutide, also a GLP-1 receptor agonist, in patients with type 2 diabetes.

Methods: We conducted a 52-week, open-label, active-controlled, phase 3 trial at 52 hospitals in China.

Timing of glucose intake drives distinct hepatic outcomes: Divergent glucose and lipid metabolism.

Objective: Excessive sugar intake is strongly associated with insulin resistance and type 2 diabetes (T2D), yet the metabolic consequences of nutrient timing-specifically glucose consumption during fasting versus feeding-remain poorly understood.

Methods: C57BL/6 mice were subjected to an every-other-day fasting (EODF) regimen and randomly divided into three groups: control (tap water only), food-glucose (FG; glucose water during feeding), and starvation-glucose (SG; glucose water during fasting). After 22 weeks, metabolic phenotypes, hepatic lipid profiles, insulin signaling markers, and hepatic transcriptomes were analyzed.

Antidiabetic drug metformin suppresses tumorigenesis through inhibition of mevalonate pathway enzyme HMGCS1.

Metformin, an antidiabetic drug, shows some potent antitumor effects. However, the molecular mechanism of metformin in tumor suppression has not been clarified. Here, we provided evidence using in vitro and in vivo data that metformin inhibited mevalonate pathway by downregulation of 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1), a key enzyme in this pathway.